投稿注册咨询:400-008-5413 销售咨询:010-6029 9110、80259978
陈也伟:Target attainment analysis and optimal sampling designs for population pharmacokinetic study on piperacillin/tazobactam in neonates and young infants PPT讲座视频 中华医学会第二十一次全国儿科学术大会
标题: Target attainment analysis and optimal sampling designs for population pharmacokinetic study on piperacillin/tazobactam in neonates and young infants
讲者: 陈也伟
单位: 复旦大学附属儿科医院
播放: 1799
论文摘要: Objectives Population pharmacokinetic (popPK) analyses for piperacillin/tazobactam in neonates and infants of less than 2 months of age have been performed previously. The results indicate that a dose of 44.44/5.56 mg/kg piperacillin/tazobactam every 8 or 12 h may not be enough for controlling infection in this population. In order to determine the appropriate dosing regimen and to provide a rationale for the development of dosing guidelines suitable for this population, further popPK studies of piperacillin/tazobactam would need to be conducted. The aim of the present study was to determine the appropriate dosing regimen and optimal sampling schedules in neonates and infants of less than 2 months of age.
Methods Pharmacodynamic profiling of piperacillin using Monte Carlo simulation was performed to explore the target attainment probability of different dosing regimens for infections caused by different isolated pathogens. D-optimal designs for piperacillin and tazobactam were conducted separately and the time that overlapped were chosen as the final sampling scheme for future popPK studies in neonates and young infants of less than 2 months of age.
Results Our findings revealed that compared to the current empirical piperacillin/tazobactam dose regimen (50 mg/kg every 12h by 5 min infusion in our hospital), the clinical outcome could be improved by increasing doses, increasing administration frequency and prolonging intravenous infusion in neonates and infants of less than 2 months of age. The following optimal sampling windows were chosen as the final sampling scheme: 0.1-0.11, 0.26-0.29, 0.97-2.62 and 7.95-11.9 h administered every 12h, 0.1-0.11, 0.22-0.29, 0.91-1.96 and 5.56-7.93 h administered every 8h, 0.1-0.11, 0.25-0.28, 0.84-1.69 and 4.55-5.94 h administered every 6h.
Conclusions The dosing regimen and sampling schedules proposed in this study should be considered in future popPK studies of piperacillin/tazobactam in neonates and infants. To the best of our knowledge, this is the first study that Monte Carlo simulation and optimal design were used for designing popPK studies of piperacillin/tazobactam.

药剂科

复旦大学附属儿科医院

该讲者其他视频
相关视频
该讲者其他论文
相关论文

l 病例讨论

作者: 刘瑞清

单位: 西安市儿童医院

来源: 中华医学会第二十一次全国儿科学术大会

l RDS预防的思考

作者: 封志纯

单位: 陆军总医院附属八一儿童医院

来源: 中华医学会第二十一次全国儿科学术大会

l 益生元在儿科中的应用

作者: 俞惠民

单位: 浙江大学医学院附属儿童医院

来源: 中华医学会第二十一次全国儿科学术大会

l 病例讨论

作者: 于莹

单位: 湖南省儿童医院

来源: 中华医学会第二十一次全国儿科学术大会

l 病例讨论

作者: 黄河玉

单位: 华中科技大学同济医学院附属同济医院

来源: 中华医学会第二十一次全国儿科学术大会

l 病例讨论

作者: 聂秀真

单位: 山东大学齐鲁儿童医院/济南市儿童医院

来源: 中华医学会第二十一次全国儿科学术大会

l 病例讨论

作者: 林先耀

单位: 杭州市儿童医院

来源: 中华医学会第二十一次全国儿科学术大会

l Noisy breathing in infants-diagnostic approach

作者: Michael S. Schechter MD, MPH

单位: Division of Pulmonary Medicine Department of Pediatrics Virginia Commonwealth University

来源: 中华医学会第二十一次全国儿科学术大会

学术交流区 (0条留言)
最新留言
产品&服务
• 学会/协会管理系统
• 会务通学术会议服务平台
• 现场注册签到管理系统
• 会场幻灯传输转播系统
• 学术会议网络直播系统
• E-Poster电子壁报系统
• 企业数字助展服务
• 花生会议管理系统
帮助中心
• 功能更新
• 常见问题
关于我们
• 公司简介
• 版权声明
• 联系我们
微信扫描
美迪康官方微信
Copyright©2007-2017 MEDCON. All Rights Reserved.北京美迪康信息咨询有限公司 版权所有. 京ICP备11011505号-31 京公网安备 11011502002826号